Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR).

Next Previous
Trial Profile

A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pioglitazone (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ACTIM

Most Recent Events

  • 27 Dec 2016 Status changed from recruiting to completed, as per the results published in the Cancer journal.
  • 27 Dec 2016 Results published in the Cancer
  • 08 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top